{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=75", "query": { "intervention": "pembrolizumab", "page": 75 }, "page_size": 10 }, "pagination": { "page": 75, "page_size": 10, "total_count": 1852, "total_pages": 186, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=76&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=74&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T17:34:20.618Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06099782", "title": "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Carcinoma", "Melanoma" ], "interventions": [ { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2023-12-26", "completion_date": "2027-02-15", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 8, "location_summary": "Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06099782" }, { "nct_id": "NCT06868277", "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "Rilvegostomig", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 830, "start_date": "2025-04-10", "completion_date": "2030-12-02", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 39, "location_summary": "La Mesa, California • Los Alamitos, California • Newark, Delaware + 36 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06868277" }, { "nct_id": "NCT05296512", "title": "Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Clear Cell Carcinoma", "Gynecologic Cancer" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elizabeth K. Lee MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2022-09-23", "completion_date": "2028-11-15", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05296512" }, { "nct_id": "NCT02965716", "title": "Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma", "Recurrent Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-06-05", "completion_date": "2026-11-04", "has_results": true, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 20, "location_summary": "Mobile, Alabama • Goodyear, Arizona • Los Angeles, California + 15 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02965716" }, { "nct_id": "NCT05525455", "title": "TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Cancer", "Oncology" ], "interventions": [ { "name": "TT-816", "type": "DRUG" }, { "name": "A PD-1 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teon Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2022-08-29", "completion_date": "2023-09-07", "has_results": false, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 5, "location_summary": "Nashville, Tennessee • Austin, Texas • San Antonio, Texas + 2 more", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05525455" }, { "nct_id": "NCT05629585", "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1174, "start_date": "2022-11-28", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 88, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05629585" }, { "nct_id": "NCT07276880", "title": "Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "HER2-Negative Breast Carcinoma", "Node-positive Breast Cancer" ], "interventions": [ { "name": "Neoadjuvant Pembrolizumab", "type": "DRUG" }, { "name": "low dose neoadjuvant boost", "type": "RADIATION" }, { "name": "High dose neoadjuvant boost", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-03-17", "completion_date": "2032-01", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07276880" }, { "nct_id": "NCT07823491", "title": "Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Resectable Liposarcoma", "Resectable Soft Tissue Sarcoma", "Resectable Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Transthoracic Echocardiography Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2026-12-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07823491" }, { "nct_id": "NCT03727880", "title": "Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lei Zheng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 28, "start_date": "2019-06-04", "completion_date": "2025-01-15", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 3, "location_summary": "Los Angeles, California • Baltimore, Maryland • San Antonio, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03727880" }, { "nct_id": "NCT05553782", "title": "Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Salivary Gland Cancer", "Adenoid Cystic Carcinoma of the Salivary Gland", "Squamous Cell Carcinoma of Head and Neck", "Head and Neck Cancer" ], "interventions": [ { "name": "Implantable Microdevice (IMD)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-11-01", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-11-07T17:34:20.618Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05553782" } ] }